Search Results

October 2, 2012

Janssen Announces Worldwide Agreement To Develop And Commercialize JAK Inhibitor For Immunological Diseases

Orally Administered Investigational Therapy Expands Global Immunology Portfolio

September 30, 2012

New ZYTIGA® (abiraterone acetate) Data on Pain and Function Presented at the ESMO 2012 Congress (European Society for Medical Oncology)

New Analyses from Phase 3 COU-AA-302 Study Also Suggest Radiographic Progression-Free Survival Positively Associated with Overall Survival

Innovative Medicine

September 28, 2012

DACOGEN® Approved In the European Union for the Treatment of Acute Myeloid Leukaemia

New treatment offers clinically significant benefit for patients

Innovative Medicine

September 28, 2012

Subcutaneous VELCADE® Approved In the EU for the Treatment of Multiple Myeloma

Simpler, easier route of administration offers improved safety and convenience, with maintained efficacy

Innovative Medicine

September 28, 2012

Janssen Connected Health Challenge Europe 2012 Launching To Spur Healthcare Innovation

Janssen Connected Health Challenge seeks transformational care ideas and offers awards totalling €30,000 to develop winning solutions

Innovative Medicine

September 27, 2012

FDA Approves Expansion of Dosing Window to Help Avoid Missed Doses in INVEGA® SUSTENNA® Updated Product Label

Additional Prescribing Information Revisions Also Reflected in Updated Product Label

Innovative Medicine

September 18, 2012

Janssen Submits Application to FDA Requesting Approval of SIMPONI® Intravenous Formulation for Treatment of Moderately To Severely Active Rheumatoid Arthritis

Innovative Medicine

September 10, 2012

Johnson & Johnson Symposium Honors 2012 Recipients of the Dr. Paul Janssen Award for Biomedical Research

Dr. Victor Ambros and Dr. Gary Ruvkun Honored for Discovery of microRNAs;Symposium Celebrates the Power of Science to Change the World

Research

September 7, 2012

Janssen Research & Development Submits Complete Response to the U.S. FDA on XARELTO® (rivaroxaban) for the Reduction of Secondary Cardiovascular Events in Patients with Acute Coronary Syndrome

Supplemental New Drug Application for XARELTO® to reduce the risk of stent thrombosis in patients with acute coronary syndrome also resubmitted

Innovative Medicine

September 5, 2012

U.S. FDA Grants Priority Review to Bedaquiline (TMC207) for Multi-Drug Resistant Tuberculosis Treatment

Search Results

No Results

Search Results

You are now leaving jnj.com/innovativemedicine